Connor Clark & Lunn Investment Management Ltd. trimmed its position in shares of Repligen Co. (NASDAQ:RGEN) by 11.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,175 shares of the biotechnology company’s stock after selling 650 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Repligen were worth $306,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in RGEN. Huntington National Bank purchased a new position in Repligen in the first quarter valued at approximately $25,000. Mascoma Wealth Management LLC purchased a new position in Repligen in the first quarter valued at approximately $41,000. Enlightenment Research LLC purchased a new position in Repligen in the fourth quarter valued at approximately $42,000. Private Capital Group LLC increased its stake in Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 628 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in Repligen by 485.1% in the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 1,043 shares during the last quarter. Hedge funds and other institutional investors own 84.92% of the company’s stock.

Shares of Repligen stock opened at $69.49 on Tuesday. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of 95.19, a P/E/G ratio of 4.22 and a beta of 1.00. Repligen Co. has a 52 week low of $43.02 and a 52 week high of $72.45. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.84 and a current ratio of 2.18.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The company had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The firm’s revenue was up 35.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 earnings per share. Analysts anticipate that Repligen Co. will post 0.94 EPS for the current fiscal year.

RGEN has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Wednesday, May 1st. ValuEngine lowered shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Finally, BidaskClub upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Thursday, May 30th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $64.20.

In other news, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the transaction, the director now directly owns 35,975 shares in the company, valued at $2,408,166.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jon Snodgres sold 6,467 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $58.54, for a total transaction of $378,578.18. Following the transaction, the chief financial officer now owns 21,543 shares in the company, valued at $1,261,127.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,017 shares of company stock worth $1,580,895. Insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Connor Clark & Lunn Investment Management Ltd. Sells 650 Shares of Repligen Co. (RGEN)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/connor-clark-lunn-investment-management-ltd-sells-650-shares-of-repligen-co-rgen/3030929.html.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.